Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent cancer and infectious diseases, announces today that it has appointed Mariem Charafeddine as its new chief medical officer.
Mariem brings over 15 years’ experience in the biopharmaceutical industry, spent both advancing the clinical development and commercialisation of infectious disease products, and in delivering post-marketing monitoring of licensed medical products. She has also previously worked in international medical leadership roles and drug development in infectious diseases.
“We are delighted to have Mariem join our team as we advance towards the Phase IIb read-outs of our lead clinical program in influenza,” said Tom Evans, Vaccitech CEO.
He continued, “Her wide-ranging clinical development and post-marketing expertise in infectious diseases also puts us in great stead ahead of first in human studies for our HPV and HBV therapeutics. We look forward to her input on how best to develop our vaccines for the patients that need them.”
By: Anna Smith
Source: Pharma Times
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.
Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.
Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”
